Candel Therapeutics Inc Cash Flow Conversion Efficiency
Candel Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Candel Therapeutics Inc (CADL) has a cash flow conversion efficiency ratio of -0.131x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.04 Million) by net assets ($138.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Candel Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Candel Therapeutics Inc from 2019 to 2025. This chart illustrates how Candel Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Candel Therapeutics Inc stock price for real-time trading data and today's change.
Candel Therapeutics Inc Cash Flow Conversion Ratio Explained
Candel Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Candel Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Candel Therapeutics Inc ranked by their cash flow conversion efficiency. Also see CADL market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NORVA24 GROUP AB (PUBL.)
F:WG0
|
N/A |
|
uPI Semiconductor Corp
TW:6719
|
0.020x |
|
Aeva Technologies, Inc. Common Stock
NASDAQ:AEVA
|
2.083x |
|
Sumber Global Energy Tbk Pt
JK:SGER
|
0.029x |
|
Hingham Institution for Savings
NASDAQ:HIFS
|
0.023x |
|
Hangzhou Huning Elevator Parts Co Ltd
SHE:300669
|
0.008x |
|
Liaoning Hongyang Energy Resource Invest Co Ltd
SHG:600758
|
0.046x |
|
Royce Micro Cap Closed Fund
NYSE:RMT
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Candel Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Candel Therapeutics Inc from 2019 to 2025. Review financial flexibility index of Candel Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $51.92 Million | $-38.31 Million | -0.738x | -81.10% |
| 2024-12-31 | $66.33 Million | $-27.02 Million | -0.407x | +84.84% |
| 2023-12-31 | $12.74 Million | $-34.24 Million | -2.687x | -308.04% |
| 2022-12-31 | $47.71 Million | $-31.42 Million | -0.658x | -90.09% |
| 2021-12-31 | $64.14 Million | $-22.22 Million | -0.346x | -189.98% |
| 2020-12-31 | $-23.56 Million | $-9.07 Million | 0.385x | -40.23% |
| 2019-12-31 | $-8.04 Million | $-5.18 Million | 0.644x | -- |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of … Read more